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Abstract
Aims/hypothesis In vitro studies point to a toxic effect of
high glucose and non-esterified fatty acids on beta cells.
Whether elevated levels of glucose and lipids induce beta
cell loss in vivo is less clear. The domestic cat has recently
been proposed as a valuable animal model for human type
2 diabetes because feline diabetes shows several similarities
with diabetes in humans, including obesity-induced insulin
resistance, impaired beta cell function, decreased number of
beta cells and pancreatic amyloid deposition.
Methods We infused healthy cats with glucose or lipids for
10 days to clamp their blood concentrations at the approx-
imate level found in untreated feline diabetes (glucose: 25–
30 mmol/l; triacylglycerols: 3–7 mmol/l).
Results Glucose and lipid levels were adequately targeted.
Plasma non-esterified fatty acids were increased by lipid
infusion 1.7-fold. A dramatic and progressive decline of
plasma insulin levels was observed in glucose-infused cats
beginning after 2 days of hyperglycaemic clamp. In contrast,
plasma insulin concentration and glucose tolerance test were
not affected by hyperlipidaemia. Compared with controls,
glucose-infused cats had a 50% decrease in beta cells per
pancreatic area. Apoptotic islet cells and cleaved caspase-
3-positive beta cells were observed in glucose-infused
cats only.
Conclusions/interpretation Sustained hyperglycaemia but
not hyperlipidaemia induces early and severe beta cell dys-
function in cats, and excess glucose causes beta cell loss via
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apoptosis in vivo. Hyperglycaemic clamps in cats may
provide a good model to study the pathogenesis of glucose
toxicity in beta cells.
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Introduction
Based on results from rodent and human islet cells in culture,
poorly controlled hyperglycaemia and hyperlipidaemia in
diabetic patients may negatively affect beta cells, leading to a
vicious cycle of progressive deterioration of beta cell
function and ultimately to beta cell loss [1]. The detrimental
effects of sustained high glucose and lipid levels on insulin
secretion and beta cell viability are referred to as glucotox-
icity and lipotoxicity [2, 3].
In vitro studies demonstrated that human beta cells exposed
to high glucose levels have a higher rate of apoptosis [4, 5].
Recently, however, the role of excess glucose on beta cell
apoptosis in human diabetes was questioned based on a post-
mortem study [6]. In that study, humans with recent-onset
type 1 diabetes had only a modest degree of apoptosis in the
remaining beta cells, despite prevailing hyperglycaemia in
most individuals [6]. Similar to the in vitro effects of high
glucose levels, NEFA seem to be harmful to beta cells when
present at high concentrations. High levels of saturated
NEFA, in particular palmitate, induce apoptosis indepen-
dently from glucose levels in cultured human and rat islets
[7, 8].
Several groups used a variety of glucose and lipid infu-
sion protocols to investigate the direct effects of hyper-
glycaemia and hyperlipidaemia on beta cells in vivo [9–19].
In previous studies performed in rodents, glucose and lipid
solutions were administered at a constant rate and for only
2–4 days. Constant rate infusion, however, does not allow
the maintenance of a specific level of hyperglycaemia or
hyperlipidaemia. In most studies, hyperglycaemia and
hyperlipidaemia were short-lasting or of mild degree, and
beta cell dysfunction and loss were not consistently shown.
To investigate the mechanisms of glucotoxicity and lipo-
toxicity in vivo, infusion protocols should allow sustained
and long-term hyperglycaemia or hyperlipidaemia at spe-
cific levels. Targeting blood glucose and lipid levels within
a predefined range can be achieved by frequently adjusting
the infusion rate. Based on our experience with pets,
domestic cats can be amenable to such chronic infusion
studies.
The present study was therefore conducted to test whether
sustained high levels of glucose or lipid lead to beta cell
dysfunction and beta cell loss in vivo. Cats provide an
interesting model because they spontaneously develop a form
of diabetes very similar to human type 2 diabetes [20–22].
Diabetic cats are often middle aged, a genetic predisposition
is described, obesity leading to insulin resistance is a major
risk factor, and impaired beta cell function is present. The
most striking histological similarity between human type 2
diabetes and the disease in cats is amylin-derived islet
amyloidosis. It is found in more than 80% of diabetic
felines. Most diabetic cats have beta cell loss of at least 50%
[22–26]. Here, cats were infused for 10 days with glucose or
lipids to clamp their blood concentrations at the approximate
level found in untreated feline diabetes (glucose 25–
30 mmol/l; triacylglycerols 3–7 mmol/l) [27, 28].
Methods
Animals and infusions Twenty-two neutered male, 15- to
18-month-old, healthy domestic shorthair cats (Charles
River, L’Arbresle, France) were used following principles
of laboratory animal care (Veterinary Office of Zürich,
Switzerland, # 51/2007).
Cats were randomly divided into four groups. Groups I,
II and III were infused over 10 days through a jugular
catheter. Group I (six cats) received 50% glucose added to
saline. Blood glucose was evaluated six to 12 times daily
and the infusion rate was adjusted to target levels at 25–
30 mmol/l. Group II (six cats) received lipids (Lipovenoes
10%; Fresenius-Kabi, Bad Homburg, Germany). The lipid
composition is given in Electronic supplementary material
(ESM) Table 1. Blood triacylglycerols were measured two
or three times daily to target levels at 3–7 mmol/l. Group III
(five cats) served as the control and was infused with saline.
During the 10-day infusion, cats were housed in single cages.
The remaining five cats (group IV) served as additional
controls; they were not infused and were group-housed
during the study. They allowed the investigation of the
potential confounding effect of experiment-induced stress on
glucose and lipid metabolism.
Biochemical measurements Plasma glucose was measured
by a colorimetric hexokinase/glucose-6-phosphate dehydro-
genase method, and triacylglycerols were measured by a
colorimetric assay using glycerophosphate oxidase coupled
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to phenol and 4-aminophenazone (Roche, Vienna, Austria).
Serum sodium and potassium were analysed with the ion-
selective electrode method (Roche). Serum NEFAwere mea-
sured using the NEFA-C kit (Wako, Richmond, PA, USA),
plasma β-hydroxybutyrate with the 3-hydroxybutyrate de-
hydrogenase method (Randox, Crumlin, UK).
A cross-reacting porcine insulin radioimmunoassay
(Linco, St Charles, MO, USA) was validated for cats (see
ESM Validation of the porcine insulin radioimmunoassay
for use in cats). Serum cortisol was measured by a competitive
chemiluminescent immunoassay previously validated in cats
(Bayer, Tarrytown, NY, USA) [29].
The acute-phase proteins of inflammation α1-acid
glycoprotein and serum amyloid A were measured in
plasma using a feline-specific radial immunodiffusion test
and ELISA (Tridelta, Bray, Ireland).
Assessment of beta cell function During the 10-day infusion
in groups I–III overnight fasting blood samples were
collected through the jugular catheter daily at 08:00 hours
to measure glucose and insulin. An IVGTT was performed
under anaesthesia in groups I–III 1 h after the 10-day
infusion. Group IV was also admitted to the IVGTT. A
glucose bolus of 1 g/kg was administered via the jugular
catheter. Glucose and insulin were measured before the
bolus and from 5 to 120 min thereafter. To estimate beta
cell function the insulin secretion index was calculated (see
ESM Insulin secretion in cats) [30]. After IVGTT, cats were
killed and the pancreas was excised.
Insulin content of the pancreas Pancreatic insulin content
was measured in a tissue specimen from the pancreas left lobe
and 24 h later homogenised in 0.18 mol/l HCl in 70% ethanol.
Results were normalised to the sample’s protein content
measured by spectrophotometry (ND-1000, NanoDrop,
Wilmington, DE, USA) at 280 nm.
Islet pathology Right and left lobes, and the body of the
pancreas were examined. One aliquot of each was formalin-
fixed for 24 h and paraffin-embedded. An additional aliquot
collected from the left lobe was snap-frozen in liquid
nitrogen and stored at −80°C.
Paraffin sections were stained with haematoxylin and
eosin (H&E) for histomorphometry. For islet amyloid
deposits, additional sections were stained with thioflavine-T
and Congo red. For glycogen, frozen tissue sections were
stained with periodic acid–Schiff’s reagent (PAS) with or
without diastase digestion (1% α-amylase from Bacillus
subtilis; Sigma-Aldrich, Buchs, Switzerland). A frozen
section was stained with Oil Red O to detect islet accu-
mulation of lipids.
Immunohistochemical staining procedures for insulin,
amylin, NK6 homeobox 1 (NKX6.1), glucagon, cleaved
caspase-3, antigen identified by monoclonal antibody Ki-67
(Ki67), proliferating nuclear antigen (PCNA) and myelo-
peroxidase (for neutrophils) were performed as described in
ESM Histochemistry methods.
Insulin-, amylin- and glucagon-positive areas relative to
the pancreatic area were calculated using ImageJ software
(http://rsb.info.nih.gov/ij/) on 15 pictures collected from
each cat at ×4 magnification. Large vessels, ducts and
interlobular tissue were excluded from measurements.
The number of beta cells relative to the pancreatic area was
calculated by counting NKX6.1-positive nuclei in sections
that were double-stained with insulin and NKX6.1. Twenty
pictures were collected from each cat at ×10 magnification
using Image J.
Five-thousand cells were used to calculate the number
of apoptotic islet cells, cleaved caspase-3-positive beta
cells, Ki67-positive or PCNA-positive beta cells, and islet
myeloperoxidase-immunostained neutrophils. Counts were
not performed in small islets with the longer axis below
50μm.Neutrophils were also counted in the exocrine pancreas
in 50 microscopic fields at ×40 magnification, excluding those
in large vessels.
Isolation of islets, RNA isolation, reverse transcription and
quantitative analysis of mRNA Islet isolation was per-
formed as described by E. Zini and C. E. Reusch
(unpublished results). Total RNA from islets was extracted
using the RNeasy Mini Kit (Qiagen, Basel, Switzerland).
Genomic DNA contamination was eliminated by including
DNase treatments (DNase-Free DNase Set, Qiagen). RNA
quality was assessed by gel electrophoresis. The comple-
mentary DNA (cDNA) was obtained from 1 μg samples of
RNA (Omniscript RT-Kit, Qiagen) in the presence of 13 U
of RNasin (Promega, Madison, WI, USA).
Islet cDNA was subjected to quantitative real-time PCR
using feline-specific oligonucleotides established for insu-
lin, Fas receptor, the caspase-8 inhibitor Flip (also known
as Cflar), the chemokines Il8 and Mcp-1 (also known as
Ccl2) and the housekeeping gene cyclophilin A (ESM
Table 2). Published sets of primers and probes for feline Il6,
Il1b, Tnfα (also known as Tnf) and the control gene Gapdh
were also used (ESM Table 2) [31].
For SYBR-Green and probe-based assays, PCR were
performed (E. Zini and C. E. Reusch, unpublished results).
The cDNA samples were run in triplicate and transcripts
were quantified using the relative standard curve method.
Gene expression was normalised to cyclophilin A and
Gapdh.
Statistical analysis
Data are expressed as mean±SE. Data were analysed using
GraphPad Prism 4.0 (GraphPad, San Diego, CA, USA).
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Results in glucose-, lipid- or saline-infused cats were
compared using the Kruskal–Wallis and Dunn’s tests.
Experimentally induced stress was assessed by comparing
the results of group III (saline) and group IV (no infusion)
using a Mann–Whitney test. Significance was set at p<0.05.
Pathology slides were evaluated in a blinded manner by
two investigators (E. Zini, A. Perren or R.S. Heller).
Results
Ten-day hyperglycaemic and hyperlipidaemic clamps are
well tolerated in cats One cat receiving glucose was used
as a pilot. Glucose was well targeted between 25 and
30 mmol/l from day 3 of infusion (ESM Fig. 1). The cat
tolerated glucose infusion without obvious discomfort. This
cat was not used for further analyses.
In the remaining five glucose-infused cats, the expected
glucose range (25–30 mmol/l) was reached within 3–5 h
after infusion onset and was maintained for ten consecutive
days (Fig. 1a). Food intake appeared unaltered and, based
on daily physical examinations and electrolyte monitoring,
the cats were considered in good health (not shown). With
urine dipstick testing (Combur10-Test, Roche) severe
glucosuria (4+) was observed from day 1. Ketonuria was
never detected. At the end of the infusion plasma β-
hydroxybutyrate levels were not different between glucose-
infused cats, cats receiving saline and animals that were not
infused (glucose: 179±46 μl/l; saline: 180±32 μl/l; no
infusion: 157±23 μl/l). Mean body weight (BWm) was
unchanged from baseline after 10 days of glucose infusion
(BWm day 0: 4.14 kg; BWm day 10: 4.10 kg; BWm
difference:1.0%) (Fig. 1b).
Triacylglycerols were targeted at 3–7 mmol/l for most of
the infusion period in lipid-infused cats (Fig. 1c). For 2 days,
hyperlipidaemia was difficult to target in three cats and
triacylglycerol levels transiently reached 23–45 mmol/l.
During that time, two of the cats showed lethargy that rapidly
resolved after reduction of the lipid infusion rate. The NEFA
area under the curve calculated above zero was significantly
1 2 3 4 5 6 7 8 9 10
3
4
5
6
20
25
30
35
Time (days)
Time (days)
Time (days)
Bl
oo
d 
gl
uc
os
e 
(m
mo
l/l)
Pre Post Pre Post Pre Post
3.0
3.5
4.0
4.5
5.0
5.5
 Saline               Glucose              Lipids
Bo
dy
 w
ei
gh
t (k
g)
1 2 3 4 5 6 7 8 9 10
0.2
0.7
1.2
1.3
3
7
14
21
Pl
as
m
a 
tri
ac
ylg
lyc
er
ol
s 
(m
mo
l/l)
2 3 4 5 6 7 8 9
0.0
0.5
1.0
1.5
2.0
N
EF
A 
(m
mo
l/l)
a
b
c
d
Fig. 1 a Blood glucose levels during the 10 day infusion period in
glucose-infused (black rhombus), lipid-infused (white triangle) and
saline-infused (black triangle) cats. Hyperglycaemia in glucose-infused
cats was maintained at 25–30 mmol/l (shaded area). Blood glucose
levels slightly increased in lipid-infused cats between days 5 and 10
(average increase above baseline 0.7 mmol/l), but remained within the
limits reported for healthy cats (Clinical Laboratory of the Vetsuisse
Faculty, University of Zürich; reference range: 3–8 mmol/l). Values are
expressed as mean±SE. b Body weight of saline-, glucose- or lipid-
infused cats before (Pre) and after (Post) infusion. After infusion, body
weight decreased slightly in saline-infused cats (average difference
4.3%), was stable in glucose-infused cats (average difference 1.0%) and
significantly increased in lipid-infused cats (average difference 10.7%;
p<0.05). Individual values are shown. c Triacylglycerol levels during
the 10 day infusion period in glucose-infused (black rhombus), lipid-
infused (white triangle) and saline-infused (black triangle) cats. In lipid-
infused cats hyperlipidaemia was maintained over 10 days of infusion.
Plasma triacylglycerol levels were adequately maintained at 3–7 mmol/l,
in particular between days 3 and 10 (shaded area). Values are expressed
as mean±SE. d Circulating NEFA were measured eight times (from
day 2 to 9) during the infusion period in each glucose-infused (black
rhombus), lipid-infused (white triangle) and saline-infused (black
triangle) cat. Values are expressed as mean±SE. The calculated area
under the curve for NEFA was higher in lipid-infused cats than in
saline-infused cats (p<0.05) or glucose-infused cats (p<0.01)
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higher in lipid-infused cats than in saline-infused (p<0.05) or
glucose-infused (p<0.01) cats (Fig. 1d). In some cats,
however, NEFA levels varied during infusion. In all lipid-
infused cats, food intake, physical examination and electro-
lytes were normal throughout infusion. Lipaemic plasma
prevented quantification of β-hydroxybutyrate. Body weight
significantly increased by 10% after 10 days of infusion in all
lipid-infused cats (BWm day 0: 3.92 kg; BWm day 10:
4.33 kg; p<0.05) (Fig. 1b).
In saline-infused cats, food intake, physical examination
and electrolytes were normal. Body weight decreased slightly
during infusion (BWm day 0: 4.18 kg; BWm day 10:
4.00 kg; BWm difference: 4.3%) (Fig. 1b).
As an indicator of stress, plasma cortisol was measured
in cats from groups I–III at the end of infusion. Cortisol
levels were not different between glucose-, lipid- or saline-
infused cats (glucose: 71.7±5.5 nmol/l; lipids: 66.2±
16.6 nmol/l; saline: 121.4±22.1 nmol/l). Cats in group IV
(no infusion) had significantly lower cortisol concentrations
than saline-infused cats (27.6±13.8 nmol/l; p<0.05).
Beta cell function is severely impaired by 10 days of
glucose infusion but not lipid infusion On day 1, glucose-
infused cats had a tenfold increase in morning plasma
insulin compared with baseline. On day 2 insulin levels
markedly declined and remained stable until day 4. There-
after, despite prevailing hyperglycaemia, morning insulin
dropped further to concentrations close to the detection
limit of the assay by day 10 (Fig. 2a).
In cats on triacylglycerol infusion, blood glucose was
slightly elevated from day 4 to 10 compared with saline-
infused cats (Fig. 1a). Cats with hyperlipidaemia had insulin
concentrations similar to cats on saline throughout the infusion
period except for day 1–2, where one single cat transiently had
higher levels (Fig. 2a). This cat concurrently had two of the
mentioned episodes of severe hyperlipidaemia.
One hour after the end of infusion an IVGTT was
performed. Glucose-infused cats had no stimulation of
insulin secretion. Lipid-infused cats had a glucose-induced
secretory response similar to controls (Fig. 2b). The insulin
secretion index was significantly lower in glucose-infused
cats than in saline- (p<0.05) and lipid-infused cats (p<
0.05) but did not differ between the other groups (Fig. 2c).
The insulin-positive area in the pancreas is markedly
decreased after 10 days of glucose infusion but not lipid
infusion In glucose-infused cats, morphometric analysis of
sections stained for insulin showed severe reduction of the
insulin-positive area relative to the pancreatic area. On
average, the insulin-positive area was 80% smaller in
glucose-infused than in saline-infused cats (Fig. 3a,b).
Lipid-infused and saline-infused cats were similar, no
difference was observed between controls.
In glucose-infused cats insulin immunostaining was
condensed at the periphery. In beta cells lined by capillaries
it was often selectively located towards the cytoplasmic
membrane adjacent to the endothelial cells. In the other
groups insulin was homogeneously distributed throughout
the cytoplasm (Fig. 3c).
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Fig. 2 a Plasma insulin levels during the 10 day period of glucose,
lipids and saline infusion in cats. In glucose-infused cats (black
rhombus) insulin concentrations markedly increased during the first
24 h and progressively decreased thereafter. In lipid-infused cats
(white triangle) insulin concentrations did not differ from those in
saline-infused cats (black triangle). Values are expressed as mean±SE.
b Insulin levels during the IVGTT performed 1 h after the 10 day
period of infusion. Insulin levels did not increase in glucose-infused
cats (black rhombus) whereas lipid-infused cats (white triangle),
saline-infused cats (black triangle) and cats without infusion (black
square) had a similar insulin response. Values are expressed as mean±
SE. c Insulin secretion index derived from the IVGTT (formula in
ESM Insulin secretion in cats). The insulin secretory index was
significantly lower in glucose-infused cats than in cats infused with
saline (p<0.05) or lipids (p<0.05). Values are expressed relative to
one cat without infusion; individual values and means are shown
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The insulin content of pancreatic specimens was reduced
in four of the glucose-infused cats (Fig. 3d).
The amylin- and glucagon-positive areas relative to the
pancreatic area were not different between groups (not
shown). However, the amylin-positive area showed a
relatively large variation of up to 200% (threefold difference)
in cats infused with saline or cats without infusion. This
variation may be a confounding factor to reliably detect
differences in the amylin-positive area between groups.
Similar to insulin immunostained sections, amylin immuno-
staining in glucose-infused cats was unevenly distributed in
the cytoplasm of several beta cells. To exclude the possibility
that deposits of amylin-derived amyloid were included in the
measurement of the amylin-positive area, sections were
stained with thioflavine-T and Congo red. Amyloid deposits
were not detected with either method in any cat.
Severe loss of beta cells occurs after a 10 day glucose infusion
but not lipid infusion Beta cell number was estimated by
counting beta cell nuclei stained with NKX6.1 relative to
the pancreatic area. Compared with the number of beta cells
in saline- or lipid-infused cats, beta cells in glucose-infused
cats were reduced by about half (p<0.05) (Fig. 4a,b). This
was also evident when islet cell nuclei were evaluated on
H&E-stained sections because the majority of islet cells
appeared to contain clear cytoplasm and considerable areas
of the islets appeared devoid of nuclei (Fig. 4c).
Apoptosis contributes to beta cell loss in glucose-infused
cats We detected apoptotic islet cells in glucose-infused cats
only. Based on morphological criteria, four of five glucose-
infused cats had islet cells with typical pycnosis or karyor-
rhexis (Fig. 5a,b). Islet cells with these apoptotic features
were not found in the other groups. Using immunostaining
for cleaved caspase-3, three of four glucose-infused cats with
pycnosis or karyorrhexis had positive beta cells (Fig. 5c).
The number of proliferating beta cells as assessed by
insulin and Ki67 or PCNA immunostaining was not different
between groups (Fig. 5d,e).
Glucose infusion induces beta cell accumulation of glyco-
gen To investigate the nature of the clear cytoplasm
identified in the islets of glucose-infused cats (Fig. 4c),
staining for glycogen and lipids was performed. Predigestion
of glycogen with diastase followed by PAS staining
suggested that the islets of glucose-infused cats accumulated
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Fig. 3 a Insulin immunostaining (pink) of feline pancreatic islets.
Main image shows overview of a pancreatic section. Portions marked
with square frame within main image designate regions shown at
higher magnification (inserts). b The insulin-positive area was signi-
ficantly smaller in glucose-infused cats than in cats infused with saline
(p<0.05) or lipids (p<0.05). The insulin-positive area did not differ
between the two control groups. Insulin-positive area was calculated
as a percentage of the total pancreatic area and values are expressed
relative to one cat without infusion; individual values and means are
shown. c Pancreatic islet of a glucose-infused cat. In the beta cells of
glucose-infused cats, insulin immunostaining (pink) was mainly localised
at the cell periphery. In the same cats, insulin immunostaining in beta
cells lined by capillaries was often shifted towards the cytoplasmic
membrane adjacent to endothelial cells (arrowheads). d Insulin content
of the pancreas. In four glucose-infused cats the insulin content of
pancreatic specimens was lower than in saline-infused cats. Insulin
levels were normalised to the protein content measured with a
spectrophotometer (wavelength: 280 nm) and values are expressed
relative to one cat without infusion; individual values and means are
shown
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glycogen (Fig. 6). Based on Oil Red O staining, triacylgly-
cerols were not stored in islets of glucose-, lipid- or saline-
infused cats.
Insulin mRNA expression is downregulated after a 10 day
glucose infusion but not lipid infusion Average expression
of insulin mRNA was approximately fourfold lower in
isolated islets of glucose- than saline-infused cats (p<0.05)
(Fig. 7). No difference was observed between lipid- and
saline-infused cats. Insulin mRNA was higher in saline-
infused cats than in cats without infusion (p<0.05).
Comparable results were achieved when insulin transcripts
were normalised with Gapdh or cyclophilin A (not shown).
Quantities of mRNA for Fas and Flip were similar between
groups (not shown).
Glucose and lipid infusion induce systemic inflammatory
reaction After 10 days of infusion, circulating levels of
α1-acid glycoprotein, but not serum amyloid A, were
significantly increased in glucose- and lipid-infused cats
compared with saline-infused cats (p<0.05). Control groups
did not differ (ESM Fig. 2a).
Messenger RNA levels of cytokines and chemokines
(Il6, Il1b, Tnfα, Il8, Mcp-1) assessed in isolated islets did
not differ between groups (not shown).
Glucose- or lipid-infused cats had islet neutrophil num-
bers similar to those of saline-infused cats (myeloperoxidase
immunostaining) (ESM Fig. 2b,c). However, glucose-
infused cats had significantly higher counts compared with
lipid-infused cats (p<0.05). Furthermore, glucose-infused
cats appeared to have more neutrophils in the exocrine
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Fig. 4 a Number of beta cells
relative to the pancreatic area.
NKX6.1-positive cells were
counted in pancreatic sections
double stained with NKX6.1
and insulin. The number of beta
cells was reduced by approxi-
mately half in glucose-infused
cats compared with saline-
infused cats (p<0.05) or lipid-
infused cats (p<0.05).
b NKX6.1 (black) and insulin
(brown) immunostaining of
pancreatic islets in cats (×40).
Few NKX6.1-positive nuclei are
observed in the islet of the
glucose-infused cat. In the same
cat insulin staining is decreased.
Values are expressed relative to
one cat without infusion; indi-
vidual values and means are
shown. c H&E staining of pan-
creatic islets in cats (×40). In the
glucose-infused cat a large area
on the left side of the islet
appears devoid of nuclei and
includes several vacuoles
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Fig. 5 a H&E staining of three pancreatic islets of glucose-infused
cats (×40). Arrows show nuclei with morphological features of
apoptosis. b Numbers of islet apoptotic cells. Glucose-infused cats
had significantly more islet apoptotic cells than cats infused with
saline (p<0.05) or lipids (p<0.05). Individual values and means are
shown. c Numbers of proliferating beta cells. The number of
proliferating cells was not different between groups. In two of the
glucose-infused cats several proliferating beta cells were observed.
Individual values and means are shown. d Triple immunostaining for
insulin (green), NKX6.1 (blue) and cleaved caspase-3 (red) of
pancreatic islets in cats (×40). An apoptotic beta cell positive for
cleaved caspase-3 is identified in the islet of a glucose-infused cat
(arrow). e Triple immunostaining for insulin (green), NKX6.1 (red)
and Ki67 (blue) of pancreatic islets in cats (×40). A proliferating beta
cell is shown in the islet of a glucose-infused cat (arrow). Proliferating
cells were also observed in the exocrine pancreas adjacent to the islet
of the other cats (arrows)
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pancreas, compared with the other groups (ESM Fig. 2d).
Neutrophils in islets or exocrine pancreas were not different
between controls.
Macrophages were not counted in cat islets because of
the lack of cross-reacting antibodies (ESM Table 3).
Discussion
Using long-term hyperglycaemic and hyperlipidaemic
clamps in cats, we developed an animal model suitable to
study pathogenesis of beta cell dysfunction and loss
induced by excess glucose or lipids in vivo. Plasma glucose
and lipids were successfully targeted for 10 days at the
levels of cats with untreated diabetes [27, 28]. Glucose-
infused cats were non-ketotic. Based on physical examina-
tion, food intake, body weight and electrolyte monitoring,
hyperglycaemia and hyperlipidaemia were well tolerated.
Cage rest and chronic intravenous infusion increased basal
cortisol levels compared with cats without infusion, suggest-
ing that the experimental set-up induced a slight stress
response. However, cortisol was not different between groups
infused with glucose, lipids or saline.
In contrast to previous models using rodents, in which
glucose was infused for 2–4 days [9–14], we show that
severe beta cell dysfunction is rapidly induced by sustained
hyperglycaemia in cats. Plasma insulin markedly declined
by day 2 of glucose infusion and was below baseline by
day 10. After infusion, an acute glucose bolus did not
stimulate insulin secretion. In addition, most hyperglycae-
mic cats had lower pancreatic insulin contents than saline-
infused cats. Pancreatic sections of hyperglycaemic cats had
insulin-positive areas reduced by 80%, probably as the
result of depletion of insulin stores. Furthermore, the
decrease of insulin gene transcription observed in hyper-
glycaemic cats showed that chronic overstimulation of beta
cells with glucose caused reduced insulin synthesis. To
support this notion, insulin was distributed as a thin rim at
the beta cell periphery in those cats. Because proinsulin is
concentrated in the Golgi apparatus of normal beta cells
[32], the lack of perinuclear immunostaining may suggest
that early steps in insulin synthesis were disturbed.
Collectively these findings demonstrate that sustained
hyperglycaemia strongly impairs beta cell function in cats,
and that this is the result of beta cell exhaustion and
decreased insulin gene expression.
This study supports the hypothesis that hyperglycaemia
causes beta cell loss in vivo, as indicated by the 50% decrease
in beta cell count per pancreatic area in glucose-infused cats.
This was not compensated by increased beta cell prolifera-
tion. Based on histomorphological features, hyperglycaemic
cats had large parts of most islets devoid of nuclei. In most
rodent studies, glucose infusion for 2–4 days either increased
or had no effect on beta cell mass [12, 14–17]. None of these
in vivo experiments demonstrated a demise of beta cells
after infusion. As to the reason for the reduced number of
beta cells in hyperglycaemic cats, we found that apoptotic
islet cells and beta cells positive for cleaved caspase-3 were
only present in glucose-infused cats. Apoptosis may thus
contribute to the reduced number of beta cells in hyper-
glycaemic cats. This is consistent with in vitro studies
showing that high glucose increases the rate of beta cell
apoptosis in human islets or in islets of Psammomys obesus
[4, 5, 33].
In the islets isolated from hyperglycaemic cats we found
no increase in IL-1β or the Fas receptor. Hence, in contrast
to human islets exposed to high glucose [4, 5], apoptosis of
beta cells in hyperglycaemic cats may have occurred
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Fig. 7 Relative quantities of insulin mRNA in isolated islets. Insulin
transcripts were fourfold lower in glucose-infused cats than in saline-
infused cats (p<0.05). Cats that did not receive infusion had lower
insulin expression levels than saline-infused cats (p<0.05). Values are
expressed relative to one cat without infusion; individual values and
means are shown
Saline Lipids
Glucose Diastase
Fig. 6 Feline pancreatic sections stained with PAS (×40). A
consecutive section of the glucose-infused cat was predigested with
diastase (×40). Islet loss of PAS positivity after diastase digestion
indicated that glycogen was accumulated in the islets of glucose-
infused cats
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through mechanisms that do not involve local inflammatory
reactions or Fas receptor upregulation. Of note, substantial
amounts of glycogen had accumulated in the islets of hyper-
glycaemic cats. Deposits of glycogen have been described in
the islets of diabetic humans and animals [34–36] and have
been proposed to account, at least partly, for the beta cell
secretory defects induced by excess glucose [37]. Whether
glycogen accumulation also contributes to beta cell loss has
not been studied. Recently, it was shown that beta cell
overexpression of the glycogen synthase kinase-3 gene is
associated with beta cell dysfunction and loss in rats [38].
Interestingly, this enzyme is both linked to glycogen syn-
thesis and to proliferation/apoptosis. The link between
glycogen metabolism and cell survival makes this gene a
possible candidate to explain beta cell apoptosis.
Feline beta cells are very susceptible to the effects of
marked hyperglycaemia. It is however worth noting that
part of the observed toxic changes may have been induced
by the fast increase of glucose levels in the islet milieu
rather than by the sustained hyperglycaemia. To better
mimic the natural history of feline diabetes a gradual ramp-
up of glucose levels would require infusion over several
weeks. Such a gradual increase of hyperglycaemia was not
performed because of the risk of septicaemia and for animal
welfare reasons. Clamps could also have been performed at
lower blood glucose levels to provide information upon the
mechanisms involved in earlier phases of beta cell failure.
However, our study shows the principal mechanisms of
hyperglycaemia-induced beta cell damage at levels of
hyperglycaemia seen in untreated diabetes.
In contrast to the detrimental effects of hyperglycaemia,
hyperlipidaemia leading to increased plasma levels of
NEFA did not affect basal insulin or glucose-induced
insulin secretion in the IVGTT. Insulin gene transcription
appeared to be unaffected by lipid infusion. Conflicting
results have been described with regard to the effects of
excess NEFA on insulin secretion in vivo. Studies in rats
and humans reported increased, decreased or unchanged
beta cell function [18, 19, 39, 40]. Such differences may
partly be attributable to the different infusion protocols.
Here, to mimic the in vivo milieu of diabetic cats we
targeted triacylglycerols at the concentration found in feline
diabetes [27, 28]. This led to a 1.7-fold increase of plasma
NEFA, hence similar to the twofold increase of NEFA
concentrations in untreated diabetic vs healthy cats (E. Zini
and C.E. Reusch, unpublished observation).
Hyperlipidaemia and excess NEFA levels in cats had no
effect on beta cell number and beta cell apoptosis or
proliferation. In cultured human and rat islets, exposure of
beta cells to palmitate appears toxic, whereas oleate protects
from both palmitic- and glucose-induced beta cell apopo-
tosis [7, 8]. Because the emulsion used here contained
approximately threefold higher amounts of oleate than
palmitate, it is possible that the protective effect of oleate
outweighed the negative effect of palmitate. Accumulation
of lipids and, possibly, of toxic lipid by-products was not
observed in beta cells. Thus, the present work reveals that
feline beta cells in vivo are resistant to 10 days of hyper-
lipidaemia and excess NEFA.
It is important to note that the degree of hyperlipidaemia,
particularly of NEFA, was proportionally lower than the
degree of hyperglycaemia, making direct comparison of the
two infusion regimens difficult. In addition, NEFA levels
varied widely in some cats. Therefore, it is possible that
substantial beta cell damage would have occurred in cats if
lipids had been clamped at higher concentrations and NEFA
levels had been constantly increased. Future studies will
have to show whether concurrent infusion of glucose and
lipids have a combined effect on the beta cells in vivo because
the concept of beta cell lipotoxicity is often considered
relevant only when coupled with glucotoxicity [1].
We found that both hyperglycaemia and hyperlipidaemia
induced systemic inflammation in cats, as shown by an
increased plasma concentration of α1-acid glycoprotein, the
most important feline acute-phase protein [41]. Hence,
systemic inflammation may develop in diabetic cats similar
to what has been described in human type 2 diabetes [42].
In contrast to type 2 diabetes in humans [43], we did not
observe an inflammatory reaction in islets of hyperglycae-
mic or hyperlipidaemic cats, as assessed by islet transcripts
of cytokines or chemokines and by the number of islet
neutrophils. The reason for a higher neutrophil number in
the islets and exocrine pancreas of glucose-infused cats
compared with lipid-infused cats remains unclear.
In conclusion, clamping plasma glucose and lipid levels is
feasible in cats, and the in vivo model is appropriate to study
pathogenesis of beta cell dysfunction and beta cell demise
that may occur in poorly controlled diabetes. Ten days of
hyperglycaemia severely impaired beta cell secretory capac-
ity and caused marked beta cell loss in cats, possibly via
apoptosis. Hyperlipidaemia, despite increasing NEFA levels,
did not induce beta cell dysfunction and loss in cats.
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